FDA Approves IMLYGIC™ (Talimogene Laherparepvec) As First Oncolytic Viral Therapy In The US
Go back to FDA Approves IMLYGIC™ (Talimogene Laherparepvec) As First Oncolytic Viral Therapy In The US| Amgen Inc (NASDAQ: AMGN) | Delayed: 347.46 +2.74 (0.79%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $344.72 | 52 Week High | $176.85 | |||
| Open | $348.31 | 52 Week Low | $133.64 | |||
| Day High | $349.40 | P/E | 52.33 | |||
| Day Low | $345.49 | EPS | $6.64 | |||
| Volume | 392,080 | |||||
